Clearside Biomedical

$3.40
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.05 (-1.43%) As of 7:56 PM UTC today

Why Robinhood?

You can buy or sell CLSD and other stocks, options, and ETFs commission-free!

About CLSD

Clearside Biomedical, Inc. Common Stock, also called Clearside Biomedical, is a clinical stage biopharmaceutical company, which engages in the development of drug therapies to treat blinding diseases of the eye. Its pipeline includes Suprachoroidal CLS-TA, Suprachoroidal, Suprachoroidal CLS-TA, and gene therapy. The company was founded by Samir Kumar Patel, Vladimir Zarnitsyn, Mark Prausnitz, Daniel H. White, and Henry F. Edelhauser in May 2011 and is headquartered in Alpharetta, GA. The listed name for CLSD is Clearside Biomedical, Inc. Common Stock.

CEO
George M. Lasezkay
Employees
33
Headquarters
Alpharetta, Georgia
Founded
2011
Market Cap
189.54M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
512.45K
High Today
$3.58
Low Today
$3.30
Open Price
$3.57
Volume
209.95K
52 Week High
$4.53
52 Week Low
$1.10

CLSD Earnings

-$0.39
-$0.26
-$0.13
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Available Mar 10, After Hours

You May Also Like

FMC
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure